Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, HS[Park, H. S.] | - |
dc.contributor.author | Kang, B[Kang, B.] | - |
dc.contributor.author | Chon, HJ[Chon, H. J.] | - |
dc.contributor.author | Im, HS[Im, H-S] | - |
dc.contributor.author | Lee, CK[Lee, C-K] | - |
dc.contributor.author | Kim, I[Kim, I] | - |
dc.contributor.author | Kang, MJ[Kang, M. J.] | - |
dc.contributor.author | Hwang, JE[Hwang, J. E.] | - |
dc.contributor.author | Bae, WK[Bae, W. K.] | - |
dc.contributor.author | Cheon, J[Cheon, J.] | - |
dc.contributor.author | Park, JO[Park, J. O.] | - |
dc.contributor.author | Hong, JY[Hong, J. Y.] | - |
dc.contributor.author | Kang, JH[Kang, J. H.] | - |
dc.contributor.author | Kim, JH[Kim, J. H.] | - |
dc.contributor.author | Lim, SH[Lim, S. H.] | - |
dc.contributor.author | Kim, JW[Kim, J. W.] | - |
dc.contributor.author | Kim, JW[Kim, J-W] | - |
dc.contributor.author | Yoo, C[Yoo, C.] | - |
dc.contributor.author | Choi, HJ[Choi, H. J.] | - |
dc.date.accessioned | 2021-07-27T02:10:42Z | - |
dc.date.available | 2021-07-27T02:10:42Z | - |
dc.date.created | 2021-06-22 | - |
dc.date.issued | 2021-04 | - |
dc.identifier.issn | 2059-7029 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/1251 | - |
dc.description.abstract | Background: There is no clear consensus on the recommended second-line treatment for patients with metastatic pancreatic cancer who have disease progression following gemcitabine-based therapy. We retrospectively evaluated the clinical outcomes of liposomal irinotecan (nal-IRI) plus fluorouracil/ leucovorin (FL) and FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) in patients who had failed on the first-line gemcitabine-based therapy. Patients and methods: From January 2015 to August 2019, 378 patients with MPC who had received nal-IRI/FL (n = 104) or FOLFIRINOX (n = 274) as second-line treatment across 11 institutions were included in this retrospective study. Results: There were no significant differences in baseline characteristics between groups, except age and first-line regimens. With a median follow-up of 6 months, the median progression-free survival (PFS) was 3.7 months with nal-IRI/FL versus 4.6 months with FOLFIRINOX (P = 0.44). Median overall survival (OS) was 7.7 months with nal-IRI/ FL versus 9.7 months with FOLFRINOX (P = 0.13). There was no significant difference in PFS and OS between the two regimens in the univariate and multivariate analyses. The subgroup analysis revealed that younger age (<70 years) was associated with better OS with FOLFIRINOX. In contrast, older age (>= 70 years) was associated with better survival outcomes with nal-IRI/FL. Adverse events were manageable with both regimens; however, the incidence of grade 3 or higher neutropenia and peripheral neuropathy was higher in patients treated with FOLFIRINOX than with nal-IRI/FL. Conclusions: Second-line nal-IRI/FL and FOLFIRINOX showed similar effectiveness outcomes after progression following first-line gemcitabine-based therapy. Age could be the determining factor for choosing the appropriate second-line therapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER | - |
dc.subject | RANDOMIZED PHASE-II | - |
dc.subject | GEMCITABINE | - |
dc.subject | THERAPY | - |
dc.subject | OXALIPLATIN | - |
dc.subject | SURVIVAL | - |
dc.subject | TRIAL | - |
dc.title | Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, JO[Park, J. O.] | - |
dc.contributor.affiliatedAuthor | Hong, JY[Hong, J. Y.] | - |
dc.identifier.doi | 10.1016/j.esmoop.2021.100049 | - |
dc.identifier.scopusid | 2-s2.0-85100635280 | - |
dc.identifier.wosid | 000644690600004 | - |
dc.identifier.bibliographicCitation | ESMO OPEN, v.6, no.2 | - |
dc.relation.isPartOf | ESMO OPEN | - |
dc.citation.title | ESMO OPEN | - |
dc.citation.volume | 6 | - |
dc.citation.number | 2 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | RANDOMIZED PHASE-II | - |
dc.subject.keywordPlus | GEMCITABINE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | pancreatic cancer | - |
dc.subject.keywordAuthor | second-line treatment | - |
dc.subject.keywordAuthor | liposomal irinotecan | - |
dc.subject.keywordAuthor | FOLFIRINOX | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu
COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.